Brian K. Nunnally Livres

Focusing on the pharmaceutical industry, this book introduces Six Sigma fundamentals and explores variation management and reduction. It provides a conceptual framework in the first half, followed by an in-depth look at control chart theory and practice. Through case studies and statistical analysis, it illustrates practical applications for workplace improvements. The text aims to establish a comprehensive operating philosophy that enhances existing products and processes within the industry, emphasizing core concepts and their effective implementation.

Based on components already in existence, this manual details a reference design for an interplanetary spacecraft that is simple, durable, fully reusable and comprised mostly of water. Using such an accessible material leads to a spacecraft architecture that is radically simpler, safer and cheaper than conventional capsule based designs. If developed, the potential affordability of the design will substantially open all of the inner solar system to human exploration.A spacecraft that is comprised mostly of water will be much more like a living cell or a terrarium than a conventional rocket and capsule design. It will use water for many purposes before it is superheated in electric engines for propulsion, purposes which include radiation shielding, heat management, basic life support, crew consumption and comfort. The authors coined the term "spacecoaches" to describe them, as an allusion to the Prairie Schooners of the Old West, which were simple, rugged, and could live off the land.

This book is an indispensable tool for anyone involved in the research, development, or manufacture of new or existing vaccines. It describes a wide array of analytical and quality control technologies for the diverse vaccine modalities. Topics covered include the application of both classical and modern bio-analytical tools; procedures to assure safety and control of cross contamination; consistent biological transition of vaccines from the research laboratory to manufacturing scale; whole infectious attenuated organisms, such as live-attenuated and inactivated whole-cell bacterial vaccines and antiviral vaccines using attenuated or inactivated viruses; principles of viral inactivation and the application of these principles to vaccine development; recombinant DNA approaches to produce modern prophylactic vaccines; bacterial subunit, polysaccharide and glycoconjugate vaccines; combination vaccines that contain multiple antigens as well as regulatory requirements and the hurdles of licensure.